![](https://news.europawire.eu/wp-content/uploads/2024/03/evotec-logo-144x144.jpg)
(IN BRIEF) Evotec SE has made significant progress in its strategic partnership with Bristol Myers Squibb, focused on developing a molecular glue-based therapy pipeline. This success has led to $75 million in milestone payments to Evotec. The partnership, which began … Read the full press release